AbbVie Q2 Beats on Immunology Strength as Botox Shows Revival Signs

The Quick Take

• AbbVie Q2 profit and sales topped Wall Street expectations, driven by strong immunology and neuroscience franchise performance.
• Botox revenue showed signs of revival, reducing investor concerns about the aesthetics division's post-pandemic growth plateau.
• The beat reinforces AbbVie's post-Humira diversification thesis as newer drugs continue to offset biosimilar competition.

AbbVie posted a Q2 earnings and revenue beat against Wall Street consensus, with the immunology and neuroscience segments leading growth. The Botox recovery signal is particularly significant: the aesthetics market had plateaued after its post-COVID surge, and a revival in Botox demand suggests discretionary healthcare spending is holding up despite consumer price pressures. AbbVie management had guided investors toward a Botox inflection point as the division implemented new marketing programmes and expanded into newer indication areas.

For large-cap pharmaceutical peers — Johnson and Johnson, Pfizer, and Eli Lilly — the AbbVie beat raises earnings expectations for the broader sector as companies navigate the post-peak-Humira biosimilar cliff. Skyrizi and Rinvoq, AbbVie core immunology drugs, continue to capture Humira patient share, and if combined neuroscience and immunology revenues can offset the Humira annual decline by 2026, AbbVie long-awaited EPS trough may already be behind it. Sector analysts will update their trough-year models accordingly.

Key watch points include Q3 Botox volume data by geography to confirm the revival is sustainable, Skyrizi and Rinvoq combined revenue trajectory versus Humira erosion, and any update on AbbVie neuroscience pipeline (migraine, Parkinson therapeutics). The macro variable is US consumer healthcare spending under inflationary pressure: if discretionary procedures including cosmetic Botox face softness, the aesthetics recovery thesis is at risk in H2 2026.

Synthesized from 1 source.